• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Lower dose of ketorolac found to be non-inferior for pain management of renal colic

byConstance Wu
January 20, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Both 10 and 20 mgs of IV ketorolac were found to be non-inferior to 30 mg IV for the emergency pain management of renal colic.

2. The rate adverse effects across the three cohorts was found to be similar.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Renal colic is commonly encountered in the emergency department, and appropriate strategies for pain control that do not rely on opiates are of the essence. In particular, the nonsteroidal anti-inflammatory drug (NSAID) ketorolac has been shown to be as effective as opiates for pain management of renal colic; the current FDA recommended dose for emergency pain control is 30 mg IV. Ketorolac, as with other NSAIDs, is not without a risk of adverse effects, however. As such, this non-inferiority trial compared the efficacy and adverse effects of three doses of ketorolac – 30, 20, and 10 mg IV – for the management of renal colic.

Patients with severe flank or abdominal pain were included if considered to be experiencing renal colic according to provider gestalt. Patients were randomized 1:1:1. The primary outcome was the alleviation of pain as measured by the visual analogue scale (VAS), a 100 mm horizontal line with two points of “no pain” and “the worst possible pain” at either end. Secondary endpoints included pain reduction at 15-, 45-, and 60-minutes following injection, the rate of adverse effects, and the need for additional analgesia at 30-minutes. It was found that all three cohorts had a significant response to ketorolac (p < 0.001). In the non-inferiority analysis, the 10 and 20 mg doses of ketorolac were found to be non-inferior to the 30 mg dose. Furthermore, the need for additional analgesia at 30-minutes was similar across the three cohorts (p = 0.775). The most common side effects included nausea and vomiting, with similar frequencies across the three cohorts. There was a non-significant trend toward fewer side effects of any kind in the 10 mg cohort.

A particular strength of this study is its double-blinded, randomized design to minimize bias. A limitation is that the diagnosis of renal colic was based on provider gestalt; some patients included in the analysis did not undergo CT to confirm the diagnosis. It should be noted, however, that no patients included in the analysis were discharged with a different diagnosis. In all, this non-inferiority trial suggests that a lower dose of 10 mg ketorolac IV is adequate for emergency pain control among patients presenting with renal colic.

Click here to read the study in Academic Emergency Medicine

RELATED REPORTS

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

Pain may be greater driver for suicidal behavior in youths and young adults than prescription opioids

The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome

Relevant reading: Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial

In-depth [randomized, non-inferiority trial]: A total of 165 patients were included in the analysis, 55 in the 10 mg cohort (mean [SD] age = 40.38 [10.82] years, 74.5% male), 55 in the 20 mg cohort (mean [SD] age = 39.18 [9.17] years, 80.0% male), and 55 in the 30 mg cohort (mean [SD] age = 41.64 [9.82] years, 69.1% male). Among patients in the 30 mg cohort, the median VAS score at 30-minutes was improved from 90 mm at baseline to 40 mm. Similarly, the improvement was from 80 to 40 mm and from 90 to 40 mm among the 20 mg and 10 mg cohorts, respectively. The non-inferiority limit was previously determined to be 15 mm higher than the mean VAS; because the 95% confidence intervals for the 10 mg and 20 mg cohorts never passed the inferiority limit, these lower doses were found to be non-inferior.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: emergencyemergency roomketorolacNSAIDpainrenal colic
Previous Post

Early, short-term tranexamic acid does not improve clinical outcomes at 6 months in patients with subarachnoid hemorrhage 

Next Post

Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

March 30, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Pediatrics

Pain may be greater driver for suicidal behavior in youths and young adults than prescription opioids

February 11, 2022
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome

November 24, 2021
Epidural corticosteroid injections provide only short-term radiculopathy pain relief
Chronic Disease

Initial therapy with non-pharmacological agents may be preferable for lower back pain

November 22, 2021
Next Post
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19

#VisualAbstract: Chemotherapy in addition to local therapy may improve overall survival in patients aged 70 years or older with  triple-negative breast cancer

#VisualAbstract: Chemotherapy in addition to local therapy may improve overall survival in patients aged 70 years or older with triple-negative breast cancer

Compliance-linked incentives increase infant immunizations rates in rural India

Fractional doses of yellow fever vaccines are non-inferior to standard doses in seroconversion at 28 days post-vaccination 

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.